Early experience with total robotic D2 gastrectomy in a low incidence region: surgical perspectives

BMC Surg. 2022 Apr 9;22(1):137. doi: 10.1186/s12893-022-01576-1.

Abstract

Background: Few European centers have reported on robotic gastrectomy for malignancy. We report our early experience with curative-intent total robotic gastrectomy.

Materials and methods: The Intuitive Surgery Da Vinci Surgical System Xi 4 armed robot was used. Routine D2 lymphadenectomy was applied.

Results: Some 27 patients with adenocarcinoma (n = 18), hereditary cancer susceptibility (n = 8) and premalignancy (n = 1) were allocated to robotic gastrectomy, three were excluded due to inoperability during surgery. Median (range) age was 66 (18-87) years, 14 (58.3%) were females and body mass index was 25.5 (22.1-33.5) kg/m2. Total gastrectomy was performed in 19 (79.2%) and subtotal in five (20.8%) patients. One (4.2%) procedure was converted to laparotomy. Procedural time was 273 (195-427) minutes. Three (12.5%) patients were reoperated within 30 days, one (4.2%) died. Serious complications (Clavien Dindo IIIb or more) occurred in three (12.5%) patients. Postoperative hospital stay was 10 (6-43) days. Fourteen of 16 (87.5%) patients with adenocarcinoma/premalignancy received radical resections. The median number of harvested lymph nodes was 20 (11-34). Eleven (73.3%) patients with adenocarcinoma had T3/T4 tumors and 6 (40%) had TNM stage III or more.

Conclusion: Total robotic D2 gastrectomy appears feasible and safe during early introduction in a low incidence region.

Keywords: Cancer; Feasibility; Gastrectomy; Gastric cancer; Minimal invasive; Oncology; Outcome; Robotic surgery; Surgery.

MeSH terms

  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / surgery
  • Aged
  • Aged, 80 and over
  • Female
  • Gastrectomy / methods
  • Humans
  • Incidence
  • Laparoscopy*
  • Lymph Node Excision / methods
  • Retrospective Studies
  • Robotic Surgical Procedures* / methods
  • Robotics*
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / surgery
  • Treatment Outcome